Koo,

If this was a widely held company with great float, could be worth plenty but would need to disclose above 5% ownership and intent.  We the very few do not have voting control.  SAD.

Seems we have missed one important aspect, and please correct me if wrong!

What was it last year, two, three years ago, DM came out (closet) and told the gathering the next two, three years expectations.  What was it 2025 end of next testing Phase?

BOM, seems there was too many P3 end points, some unknown uncontrolled qualities.

Well when we talk about the next P3, real money comes into play.  DM has been financing this little company on expectations based on future 208 performance.  Door really closed on RVX when Phase III did not meet the 30% mark.  But P 2 b was a blow out.  Go figure. Too many end points.

Question to all, why place test end points in a FDA Phase III that are not controllable, STROKE.  Always go with a known tested outcome when so much is at stake.  Very BIG misSTAKE. 

So what is next, RVX runs out of money, Eversana wants a paycheck.  Does not look good, so stock is at 24 cents US.  How to survive, DM will not look for a partner that wants total control, not his style.  The big three, four stockholders need to make their stand, have Board require the CEO, who ever that is, to search for a buyer.  Just that resolution will drive the SP up, at least for a short time.

Or Hepalink will not budge at Board level.  Now a real problem.  HL will pick up some cheap shares, and get get of of town.

What is in it for the buyer, plenty.  We know so much more how 208 works with C 19 issues.

Add Type II fixes, HDL, CKD, what was the study that showed greater HDL lessened the chances of cancer in the colon and finally Long C19 with heart cells.  How quickly we dismiss the future.

So what gives with the FDA and current health crisis?  And where is Canada?  Where is the Board?  Frustrations abound.  sidebar and thanks for staying on this forum.  I have learned so much.